Premium
Gastrointestinal stromal tumors and leiomyosarcomas
Author(s) -
Katz Steven C.,
DeMatteo Ronald P.
Publication year - 2008
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.20970
Subject(s) - gist , medicine , leiomyosarcoma , stromal tumor , natural history , stromal cell , imatinib , imatinib mesylate , adjuvant therapy , neoplasm , oncology , pathology , cancer , myeloid leukemia
Only recently has gastrointestinal stromal tumor (GIST) been recognized as the most frequent GI mesenchymal neoplasm. Prior to the use of KIT staining, most GI stromal tumors were identified as leiomyosarcoma (LMS). For primary GIST, surgery remains the principal treatment and adjuvant imatinib may improve outcomes. Multimodality therapy may also be effective in patients with metastatic GIST. In this review, we summarize the epidemiology, clinicopathologic features, natural history, and clinical management of LMS and GIST. J. Surg. Oncol. 2008;97:350–359. © 2008 Wiley‐Liss, Inc.